Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

<p>Abstract</p> <p>Background</p> <p>Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive imm...

Full description

Bibliographic Details
Main Authors: Wang Ena, Ascierto Maria-Libera, Worschech Andrea, Kmieciak Maciej, Godder Kamar, Gowda Madhu, Marincola Francesco M, Manjili Masoud H
Format: Article
Language:English
Published: BMC 2011-10-01
Series:Journal of Translational Medicine
Subjects:
Neuroblastoma
innate immunity
adaptive immunity
prognostic biomarkers
Online Access:http://www.translational-medicine.com/content/9/1/170

Similar Items

Similar Items